Difficulty: Medium
Average Score: 80%
Practice
In which of the following conditions estrogen is not the primary drug but is added to progestin as adjuvant?
Correct answer
C
Rationale
In this scenario, the correct answer is C) Osteoporosis. Estrogen is not the primary drug in treating osteoporosis but is added to progestin as an adjuvant therapy. Estrogen helps to prevent bone loss, while progestin helps protect the uterus lining. This combination therapy is commonly used in postmenopausal women to reduce the risk of fractures associated with osteoporosis.
Option A) Dysfunctional uterine bleeding is often treated with estrogen alone, making it an incorrect choice in this context. Option B) Menopausal syndrome can be effectively managed with estrogen therapy alone, so adding progestin as an adjuvant is not necessary in this case. Option D) Atrophic vaginitis is also primarily treated with estrogen therapy to help restore vaginal tissue health and is not typically combined with progestin.
Understanding the rationale behind the use of combination therapy in osteoporosis is crucial for healthcare professionals, especially those working with postmenopausal women. This knowledge ensures appropriate and effective treatment strategies are employed to prevent complications related to bone health. Furthermore, recognizing when to combine estrogen with progestin versus using them independently is essential in optimizing patient outcomes and minimizing potential risks associated with hormone therapy.
Option A) Dysfunctional uterine bleeding is often treated with estrogen alone, making it an incorrect choice in this context. Option B) Menopausal syndrome can be effectively managed with estrogen therapy alone, so adding progestin as an adjuvant is not necessary in this case. Option D) Atrophic vaginitis is also primarily treated with estrogen therapy to help restore vaginal tissue health and is not typically combined with progestin.
Understanding the rationale behind the use of combination therapy in osteoporosis is crucial for healthcare professionals, especially those working with postmenopausal women. This knowledge ensures appropriate and effective treatment strategies are employed to prevent complications related to bone health. Furthermore, recognizing when to combine estrogen with progestin versus using them independently is essential in optimizing patient outcomes and minimizing potential risks associated with hormone therapy.